Sign in
CompletedPhase 3

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Infants

Key facts

Who runs it
Il-Yang Pharm. Co., Ltd.
Where
South Korea2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
260 people enrolled
Started
23 Oct 2024
Ended
22 Oct 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • IL-YANG FLU Vaccine Prefilled Syringe INJ.
  • Fluarix Tetra Pre-filled Syringe
Record updated
8 July 2026

Who can take part

Age
6 months to 3 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Healthy infants 'from 6 months to under 3 years of age (≥6 months and <3 years)
  • Born after normal gestation period (which is more than 37 weeks)
  • A subject's legally acceptable representative has voluntarily decided on participation and provided written informed consent after receiving and understanding a detailed explanation on this study

Who cannot take part

  • A history of influenza vaccination within 6 months prior to screening
  • Acute fever with body temperature exceeding 38.0℃ within 72 hours prior to vaccination with the IP
  • Vaccinated with other vaccines within 28 days prior to screening
  • Received immunosuppressants or immune-modifying drugs within 3 months prior to screening; ① Azathioprine, cyclosporin, interferon, granulocyte colony-stimulating factor (G-CSF), tacrolimus, everolimus, sirolimus, etc; ② Use of high-dose corticosteroids (e.g., continued use of prednisolone at a dose of ≥2 mg/kg/day in subjects weighing <10 kg for 14 days or longer or at a dose of ≥20 mg/day in subjects weighing ≥10 kg for 14 days or longer). However, inhaled, intranasal, or topical corticosteroids are permitted regardless of their dose
  • Prior use of immunoglobulin or blood products within 3 months prior to screening or their anticipated use during the study
  • Took antipyretics, analgesics, or non-steroidal anti-inflammatory drugs (NSAIDs) within 4 hours prior to vaccination with the IP
  • Participated in another clinical study within 6 months prior to screening
  • A history of severe hypersensitivity reactions (e.g., anaphylaxis) to eggs, chicken, and other components of a vaccine including those derived from chicken
  • Immuno dysfunction including immunodeficiency diseases or a family history thereof
  • A history of Guillain-Barre syndrome
  • Down's syndrome or cytogenetic disorders
  • Severe chronic diseases (e.g., cardiovascular diseases excluding controlled hypertension, respiratory diseases with respiratory failure, metabolic diseases, renal dysfunction, hemoglobinopathy, etc.) that, in the opinion of investigator, preclude a subject's participation in the study
  • Risk of serious bleeding from an IM injection such as hemophilia patients or those on anticoagulants
  • Determined ineligible based on other clinically significant medical or psychiatric findings by the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG Quadrivalent Seasonal Influenza Vaccine) in healthy infants from 6 months to under 3 years of age(≥ 6 months and < 3 years)

The 2 groups in the trial

  • IL-YANG FLU Vaccine Prefilled Syringe INJ.Treatment being tested

    Teratect Prefilled Syringe Inj. 0.5mL

  • GSK FLU Vaccine Prefilled Syringe INJ.Existing treatment, for comparison

    Fluarix Tetra Pre-filled Syringe 0.5mL

    Treatment: Fluarix Tetra Pre-filled Syringe

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase Ⅲ, Multi-national, Randomized, Double-blind, Active Controlled to Evaluate the Immunogenicity and Safety of "IL-YANG Quadrivalent Seasonal Influenza Vaccine" in Healthy Infants From 6 Months to Under 3 Years of Age (≥ 6 Months and < 3 Years)
Record updated
8 July 2026